◈ Wu Zhaohui: Deputy Chairman of the Standing Committee of the Chinese Association of Biotechnology for Medicine and Biology.

In today's rapid development of cell-based pharmaceuticals, stem cells account for 60% from the perspective of drug applications. However, in the process of cell-based pharmaceutical industry development, there are still many issues worth addressing. In this conference, it is hoped that everyone can seek interpretations from different perspectives in the industry, share personal experiences, and support new drug research and development.

[Keynote Forum Chairs]

◈ Du yanan:

Stem cells, as an important branch of cell therapy, have shown broad application prospects in the treatment of many clinically challenging diseases, representing the "high ground" of the third medical revolution after drug therapy and surgical therapy.

Globally, over 10 therapies based on mesenchymal stem cells have received FDA approval. In China, the market size has reached nearly 150 billion yuan. Meanwhile, it's also important to recognize that there is still a long way to go before practical clinical treatment with stem cell therapies. How to ensure the realization of mesenchymal stem cell separation and standardized preparation? These ongoing research results require more clinical evidence.

The report content is diverse and rich, with insights shared by experts from home and abroad, including the Chinese Academy of Engineering, the Chinese Association of Biotechnology, the Academy of Military Medical Sciences, Tsinghua University, the French National Academy of Technologies, etc. These experts showcased the technological breakthroughs achieved in the forefront of global cell science and current stages of translational medicine. They also brought international perspectives to the challenges faced by industry development.

[Nurturing Cells, Creating with Strength-CytoNiche Biotech 2023 New Product Launch Event]

CytoNiche Biotech translates cutting-edge technological concepts into innovative products. During the main forum, Dr. Yan Xiaojun, Co-founder and CTO of CytoNiche Biotech, unveiled three new products: the 3D RecomTrix™ microcarrier CW series, the 3D FloTrix® vivaFILL cell filling system, and the 3D FloTrix® megaSPIN disposable bioreactor. This sparked another round of enthusiasm at the conference and captured the guests' attention and discussions. 

CytoNiche Biotech has never stopped empowering the CGT industry in its five years of existence. With precise positioning of industry needs and technological transformation, it has established a 3D cell smart manufacturing platform, achieving closed, automated, and large-scale cell production preparation. While ensuring the quality of cell medicines, it has significantly increased production capacity to fully meet the needs of industry development, helping biopharmaceutical companies overtake the curve. The heavyweight new products launched by CytoNiche Biotech will further provide strong support for driving industry development.

[Five Sub-Forums]

The conference also featured five parallel sub-forums covering different areas such as stem cell drug development, gene therapy drug development, immune cells, exosomes, and regenerative medical technology products. Over 40 renowned experts from home and abroad were invited to discuss topics ranging from exploring the overall development path of stem cells to clinical application challenges, from novel gene editing techniques to clinical translational research, from CAR-T research to γδ T and other refined immune cell therapies. Additionally, the investment and financing forum brought project roadshows from nearly ten companies, which received considerable attention from investors.

Forum 1: Stem Cell Drug Development 

Forum 2: Gene Therapy Drug Development 

Forum 3: Immune Cells 

Forum 4: Exosomes & Regenerative Medical Technology Products 

Forum 5: Investment and Financing Project Roadshow 

[In the land of China, a bright future awaits | CytoNiche Biotech 5th Anniversary Celebration]